
Targeted Treatments Shift the Paradigm of Advanced BTC
The management of advanced biliary tract cancer (BTC) hit a turning point in 2024 with the first approvals of targeted therapies fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) and zanidatamab-hrii (Ziihera) for patients with HER2 positivity. However, the …